Featured Press Releases

Connected Pill Box Unveiled by Hello Heart to Radically Improve Medication Adherence

Connected Pill Box Unveiled by Hello Heart to Radically Improve Medication Adherence

PCI Pharma Buys Ajinomoto Althea as Part of $1B Plan to Expand Injectable Drug Manufacturing in the U.S

PCI Pharma Buys Ajinomoto Althea as Part of $1B Plan to Expand Injectable Drug Manufacturing in the U.S

  • 01 May 2025

PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO)...

ADARx doses first patient in Phase 3 STOP-HAE trial; ADX-324 receives orphan drug designation for hereditary angioedema

ADARx doses first patient in Phase 3 STOP-HAE trial; ADX-324 receives orphan drug designation for hereditary angioedema

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

Miach Orthopaedics Appoints Jamal Rushdy as President & CEO

Miach Orthopaedics Appoints Jamal Rushdy as President & CEO

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Johnson & Johnson Strengthens European Cardiac Care with the Introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Ablation Platform

Johnson & Johnson Strengthens European Cardiac Care with the Introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Ablation Platform

  • Johnson & Johnson
  • 25 Jun 2026
StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

  • StatLab Medical Products
  • 25 Jun 2026
FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

  • Ionis Pharmaceuticals, Inc.
  • 24 Jun 2026
FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

  • Ionis Pharmaceuticals, Inc.
  • 24 Jun 2026
Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

  • Zeta Surgical
  • 23 Jun 2026
Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

  • Upsher-Smith Laboratories, LLC
  • 23 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.